Chronic Myeloid Leukaemia (CML) is a blood-derived proliferative disorder, which is highly associated to a translocation of chromosomes 9 and 22 or the creation of Philadelphia chromosome Ph(+) cases, inducing the synthesis of a chimeric fusion protein, namely BCR-ABL1 (Breakpoint Cluster Region-Abelson 1 chimeric protein), which is known for driving the pathophysiology of the disease, however variants of CML are also recognized as CML Ph(-), these nonetheless account for a small percentage of the overall CML patients; posing thus the question whether BCR-ABL1 fusion protein is required for the whole of the pathophysiology of CML. Hereof, through a stochastic description, a discrete time discrete Markov chain depicts the various protein-protein interactions of BCR-ABL1 to better understand signalling pathways and time-dependent evolution of these pathways, as well as to provide prospective therapeutic protein targets to improve both the specificity of the treatment and the life-expectancy of the patients.
regions have been observed, such as in the intron 14 of BCR and the intron 2 of ABL1 (Lyu, et al., 2016) and many others: b3a2, b2a2, b3a3, b2a3, e1a2, 19a2 (Melo, 1996) .
The BCR gene is located at 22q11.23, and shows 23 exons and it is expressed widely throughout the body, it has been associated to both acute as well as to chronic myeloid leukemia , this BCR gene encodes two RNA species of 4.5 and 6.7 kbp, and its promoter region contains SP1 binding sites, it has been proposed to have a role in metabolism; the translated protein product is a phosphoprotein with serine/threonine kinase activity as well as phosphotransferase activity, this activity has been confirmed with the homologies it shows in regards to other kinases (Maru & Witte, 1991) . Some of its molecular interactions are shown in Table 1 (TyersLab, 2019) , and we may postulate six sets of types of molecules with which it interacts: signal processing (P), cell trafficking (T), cell growth (G), cell proliferation (Pr), metabolism (M), structure (S) however these sets show obvious overlap, ∩ ≠ ∅ ∧ ∩ ≠ ∅ ∧ ∩ ≠ ∅ (Table 1) .
ABL1 in turn is a protooncogene with tyrosine kinase activity which is involved in several cellular processes: cell division, adhesion, differentiation, response to stress. The activity of ABL1 protein is negatively regulated by its SH3 domain. It is displayed in various types of leukaemias. Possesses 12 exons .
The resulting fusion protein BCR-ABL1 is a 210 kDa protein, and sometimes it could be detected in healthy individuals hypothesizing the lack of potency in the transformed cell to support leukaemia (Ismail, Naffa, Yousef, & Ghanim, 2014) . The domains in BCR-ABL1 which appear to affect the protein function are the Ser/Thr kinase domain pertaining to BCR, SH1 tyrosine kinase domain and the coil-coil protein dimerization domain. This fusion protein lacks the N-terminal myristoylated region of ABL1 which causes autoinhibition of the SH1 kinase activity. Thus, should we inhibit the myristoylated domain-binding pocket we would be doing so in an effective manner, it has been done through GNF2 and it has been seen to reduce the emergence of resistant mutants (Zhang, et al., 2010) . BCR-ABL1 fusion protein promotes aberrances in apoptosis, proliferation and cell adhesion (through signalling pathways such as: JAK/STAT, PI3K/AKT, Ras/MEK, p53, MYC, beta-catenin, C/EBP ), augmenting the proliferation of granulocytes and causing the clinical features seen in the chronic phase of CML (Chereda & Melo, 2016) . The transition in time towards a blastic phase following an accelerated phase, has been proposed to be initiated through BCR-ABL1 genetic damage, and inadequate DNA repair machinery (Perrotti, Jamieson, Goldman, & Skorski, 2010) .
Treatment.
We may in first order define what a complete cytogenetic response (CCR) is, which is the absence of the Ph in ≥ 20 cells in metaphase in a bone marrow aspirate, and a major molecular response (MMR) is reached when = − 1 1 (where BCR-ABL1 stands for the concentration of the chimeric protein) is < 1 10 −3 or − log( ) > 3 (Oriana, et al., 2013) . Having these definitions as a preludium, we may say that imatinib mesylate stands as the gamechanger in CML and the course of the disease, with a recommended dose of 400 mg/day, however different doses have been proposed based upon both the MMR and CCR reached with each, the average CCR with imatinib at 400 mg is 57.67% and with 800 mg of 65.67%, while the MMR with 400 mg is 36.67% and with 800 mg is 45% (Aladag & Haznedaroglu, 2019) ; imatinib is a tyrosine kinase inhibitor which binds to the ABL1 portion of the chimeric protein, imatinib binds and stabilises the non-ATP binding conformation of BCR-ABL1 kinase domain. Imatinib has been combined in some fashions in order to promote synergy of drugs, these other compounds are arsenic, interferon-alpha, cytarabine, doxorubicin, leptomycin B, with some enhancements of imatinib properties. Resistances to imatinib have been seen and should be early characterized in order to escalate doses or to move to second line treatments (Moen, McKeage, Plosker, & Siddiqui, 2007) .
Second line treatments are dasatinib and nilotinib, the latter exhibits better CCR and MMR (CCR=87%, MMR=71% in 24 months) as well as dasatinib (CCR=86%, MMR=82%. A combination treatment of nilotinib and Peg-IFN (interferon used to be the frontline treatment of CML before the arrival of imatinib) has been proposed and shows good results in 12 months with an MMR=76% and CCR=100%. As third-line treatments, there exist some options, such as the allogenic stem cell transplantation, and tyrosine kinase inhibitors: bosutinib and ponatinib (Aladag & Haznedaroglu, 2019) .
Several combinations for tyrosine kinase inhibitors (TKI) have been proposed, such as: bosutinib or dasatinib or omatinib or nilotinib + IFN-alpha; imatinib + hydroxyurea/cytarabine/omacetaxine/homoharringtonine; ascimimib, immune modulation (nivolumab + dasatinib, avelumab + TKI), PPARgamma agonists, DPPIV inhibitors (Westerweel, te Boekhorst, Levin, & Cornelissen, 2019) , other molecules that have been used in order to inhibit CML are: arsenic trioxide (as monotherapy), hydroxychloroquine, BMS-833923, LDE225, panobinostat, ruxolitinib, zileuton (Bhatia, 2017) .
Model.
Hereby one model concerning the stochastic nature of the proteins associated with the fusion protein BCR-ABL1 in CML is displayed.
Stochastic model.
A stochastic model concerning the protein-protein interactions in CML could provides us with new ground and opportunities in therapeutic approaches in the short-and long-term future, through estimations of the most probable nodes or proteins in the network could we direct our efforts in order to develop new and more potent drugs, as well, through estimations of mean time of passage we can predict to which node our network tends to. This model may as well bring light upon the pathophysiology of the transition towards a blastic crisis. We will consider first the BCR protein network alone, followed by the one related to the ABL1 protein, and finally we will deem them as a joint set; In the thrice of cases, the models are to be discrete time discrete Markov chains.
The BCR protein has shown interactions with 87 different proteins (TyersLab, 2019), these interactions are then a stochastic process with a set of states ̂= { 1 , 2 , … , } where P stands for protein and then we can define a function f, such that :̂→ 1 where 1 = { ∈ ℤ + } is a bijective function for the states of proteins. The temporal parameter is defined as = { ∈ ℤ + } where this temporal parameter for the meantime shall be an arbitrary time unit. The rules of transition are,
→ → →
Where R stands for the presence of a relationship or interaction between de i-th and j-th proteins.
The stochastic matrix of this protein has the following shape, The complete matrix is shown ( Fig. 1 ).
If we set the initial vector to be at equilibrium, i.e., 0 = 1 86
(1 1 , … , 1 86 ), we may determine the distribution at any given moment , according to the following expression,
First, let us find some distributions at selected values of n ( Fig. 2 ). From this we can predict what the limit distribution would look like, and we can organize the proteins by their limit distribution from greater to lesser, here we will present the proteins in which the process will tend to be 95.2973% of the time from there will we be able to determine possibilities of directed therapy, and we will represent the information as logic circuits, the possible therapies ∀ ∈ ∃ ∈ | = { ∈ ℤ + } ∧ : → where A stands for the set of the drugs available.
The matrix for ABL1 protein is as shown (Fig. 3 ). We will determine the distributions when → ∞ for ABL1 ( Fig. 4) .
This model provides us with the opportunity to observe the behaviour of the signalling networks in CML, more specifically, the probability of every network to be at any given state at one moment, interestingly do we notice that neither of both nodal proteins (BCR nor ABL1) show a large stationary probability, this invites us to think that therapeutic targets in CML is made up from a larger set of molecules than we may have initially considered, and that we may be able to deliver a much more complete therapy to CML patients in such a way that the backbone treatment is one corresponding to those interacting with either BCR or ABL1, but we then have the limbs of the treatment, where we can by all means induce a thrust by considering the probability of finding any of both systems at any state (of the most probable ones). In order to compute feasible "limb"like treatments, we shall consider the drug efficacy of the molecules we will introduce, this in turn will allow us to compute the complete or total efficacy of the treatment. This feasibility must be taken in account from the stationary probability obtained above, from which we shall consider those molecules whose summed up probability equals 0.95, such that,
Where stands for the stationary probability for the system to be in the i-th state, this expression let's us find in which state the systems will be in 95% of the time. For the case of BCR protein, this means the available drugs for 63 different proteins (including BCR) and for ABL1 this means the equally available drugs for 133 different proteins, the first set of drugs let us define it as A and the second one as B,
| ∩ | > |∅|
Moreover, let us define a set C which is the set of all proteins with which BCR interacts and D as the set of all proteins with which ABL1 interacts,
Currently, the previously described sets, say A and B show the following relationships,
We define these sets,
Now, we may describe the following probability tree, Thus, they do share proteins, more specifically,
If we define a new probability space, Ω 2 = { , } with (Ω 2 ) = 1, then, this space defines those proteins that interact with both BCR and ABL1 proteins: the protein interactions corresponding to those of the chimeric protein. We can outline a new Markov chain from this probability space, such that the set of states 2 ⊆ 1 , this set of states is the sum of the probabilities in Ω 1 is ∑ =1 = 0.95, nevertheless in Ω 2 this sum results ∑ =1 = 1, these states display stationary probabilities and are shown in Fig. 5 .
Discussion.
Undoubtedly is imatinib the frontline and central treatment in CML, it indeed has changed the prognosis landscape for these patients, showing very good results in regards to the MMR and CCR, achieving 57.67% in CCR with 400 mg/day and an MMR with 400 mg/day of 36.67% (Aladag & Haznedaroglu, 2019) with a life expectancy of patients with CML of 3 years less than that of the general population and this life expectancy has been computed to be always less than that of the general population; moreover, the use of imatinib and other TKIs poses a risk predisposing to other cancers and cardiovascular morbidity (Bower, et al., 2016) . Imatinib as the medullar treatment of CML, and other tyrosine kinase inhibitors display as their mechanism of action the binding to the chimeric protein BCR-ABL1, whether to the ABL1 portion or to the BCR portion of this protein and while they have approximated the life expectancy of patients with CML to that of the general population and improved their quality of life, efforts can be made to provide alternative therapeutic approaches to CML.
Through the model previously introduced, we have computed the stationary stochastic probabilities of three Markov chains, the ones corresponding to the BCR protein, ABL1 protein and the chimeric BCR-ABL1 protein; we then selected those proteins whose sum of stationary probabilities summed = 0.95, then from those proteins, we computed a new chain, the one for the chimeric protein and its stationary probabilities. This showed that the network of proteins with which BCR-ABL1 interacts is a vast array composed of 167 proteins, including themselves, and that this network in the stationary spectrum or when the number of steps in time taken when → ∞ does favour the rationale of use of TKIs due to the fact that the stationary probabilities for BCR and ABL1 in the chimeric protein Markov chain are, 1 = 0.07784161 = 0.04530407
Because these two probabilities are the maxima of the protein array,
> >
That is, they are greater than the stationary probability of any other j-th protein in the Markov chain. This model provides us with information about how much time the network spends on each of the members of the network based upon the interactions they show, thus they spend the + 1 = 0.12314568 of time ( = 12.31457%) in these proteins, but this time is less than the eighth of the time of the network, and if good results are achieved through the inhibition of these chimeric protein (or the two states of the Markov chain), then the inhibition (or corresponding activation) of interacting proteins could improve the results in patients with CML; some proteins that show promises in this regard are those that interact both with the BCR part and the ABL1 part of the chimeric protein, ∩ 1 = , where K is the set that contains these proteins: TP53, CBL, GRB2, HSPA8, PIK3R1, UBC, SHC1, STUB1, HSP90AA1, CRK, HSPA4, CRKL, RB1, PIK3R2, KIAA1429, TRIM25, UBASH3B, NTRK1, SOS1, DOK1, XPO1, AP2M1, PTPN6, HSPD1, RAD51, HCK, LRRK1 (with their corresponding stationary probabilities shown in Fig. 6 ) this subnetwork or set of proteins contains the 43.71% of the time spent in the network. This approach could be improved by observing the signalling pathways in which BCR-ABL1 engages and as we have previously mentioned, the main pathways involved in the pathophysiology of CML through BCR-ABL1 are: beta-catenin, C/EBPalpha, JAK/STAT, PI3K3/AKT, RAS/MEK, TP53, MYC; and we may from this moment regard that some of the aforementioned proteins exist in the Markov chains (TP53, MYC, PIK3).
JAK/STAT pathway.
In the instance of the JAK/STAT pathway, there exist in the Markov chain of the chimeric protein some proteins in turn which play roles in this signalling pathway, e.g.: JAK1, SOCS1, SOCS3, SOS1, GRB2, MYC, PIK3R1, PTPN6, PIK3R2, EGFR, PDGFR (Rawlings, Rosler, & Harrison, 2004) ; by inhibiting JAK1 activity we could effectively inhibit the signalling pathway, or by means of promoting the transcription of SOCS1 or SOCS3 which effectively inhibit JAK1 through a negative feedback fashion, By inhibiting JAK1 would we be targeting = 0.00298422 of the network involved in the chimeric protein, but because of its various interactions, this probability would sum up to = 0.11778089, which would represent a larger inhibition than that represented by the inhibition of BCR or ABL1 on their own; several JAK1 inhibitors have been described, such as ruxolitinib (TyersLab, 2020) and other JAK1-selective inhibitors: filgotinib, GLPG0555, GSK2586184, INCB039110, INCB47986, ABT-494; said inhibitors encounter themselves in clinical phases I, II, IIb and on hold (Menet, Mammoliti, & López-Ramos, 2015) . Alternative manners to achieve suppression of JAK1 signaling pathway involve the JAK1-independent promotion of expression of SOCS1/3, the one for SOCS1 has been performed elsewhere through the administration of interferon-gamma (Madonna, et al., 2015) . EGFR inhibitors are currently used in different types of cancer (e.g.: non-small cell lung cancer) and are classified in three generations, some of these drugs are: gefitinib, erlotinib, afatinib, dacomitinib, neratinib, osimertinib, rociletinib, olmutinib, ASP8273, nazartinib, avitinib; some of which are either in phases I, II or III and some others have already been approved (Sullivan & Planchard, 2017) .
TP53 pathway.
TP53, when activated is due to the cellular response to an insult, either in nutrition, low oxygen levels, DNA damage, etc., this activation turns in change in the expression of genes corresponding to cellular senescence and apoptosis, it has been seen that TP53 is activated by ATR and ATM (by means of a third party protein not involved in the main protein network) and inactivated my MDM2 (Kanehisa Laboratories, 2018), the main network spends 5.196799% of its time in this subnetwork and is a feasible target in CML therapy, either by means of TP53 activation, MDM2 inhibition or ATM and ATR activation. As MDM2 inhibitors we could readily use nutlin-3 a small molecule which has been studied as a therapy in some cancers in combination with other drugs, such as 1,25-dihydroxyvitamin D(3), AZD6244, PI-103, MK-0457, perifosine, dasatinib, doxorubicin, platinum compounds (Shen & Maki, Pharmacologic activation of p53 by small-molecule MDM2 antagonists., 2011) . ATR activation can be mediated through the administration of hydroxyurea, which has been shown to perform its action by means of increasing replication stress (Landsverk, et al., 2019) .
Beta-catenin pathway.
It involves the primary condition of whether there are any Wnt ligands that may activate DVL, if the condition is not sufficed, the destruction complex will promote the ubiquitination of CTNNB1 (beta-catenin), this is possible through four proteins: APC, GSK3B, CK1, axin. If the condition is sufficed, the destruction complex will be inhibited by DVL, more specifically, DVL will inhibit the actions of GSK3B and thus of the whole complex; with this inhibition, CTNNB1 is free to roam into the nucleus and promote the expression of genes like MYC and cyclin D1 (Krishnamurthy & Kurzrock, 2018) . The inhibition of this pathway would represent the inhibition of 1.918889% of the BCR-ABL1 chimeric protein network and may be done through a series of either inhibitions or activations; we may inhibit the WNT ligands, DVL, or CTNNB1; or we may promote either the expression or the function of APC, GSK3B, CK1, axin. Regarding DVL inhibitors, we have some options, such as: niclosamide, sulindac, NSC668036, J01-017a. Now, with CTNNB1 we have some options, such as the inhibitors of the co-activators: ICG-001, PRI-724; and those of the DNA binding: PKF115-584, PKF118-310 (Krishnamurthy & Kurzrock, 2018) .
Combination therapies.
In this instance, we propose imatinib or a TKI of second-or third-line of treatment as the cornerstone of therapy, however, because this represents the inhibition of 12.314568% of the network (directly), we propose the use of a branched treatment in order to promote the inhibition of this network's signalling, Final remarks.
The prognosis for patients with CML has improved by means of the introduction of imatinib into its treatment, with the advent of different tyrosine kinase inhibitors, resistance in patients could be adverted; however, goals in both the MMR and CCR in patients with CML remain low as well as the diminishment in life expectancy of these patients versus the general population, in this paper we have attempted to provide a Markov chain model to predict the most probable interactions within the networks of the proteins involved in the pathogenesis of CML: BCR, ABL1 and the chimeric protein BCR-ABL1; and by observing the signalling pathways affected by the aberrant behaviour of the chimeric protein we could devise some adjuvant or "branch"-like therapies to the cornerstone one (tyrosine kinase inhibitors) in order to augment the probabilities of patients for a longer life expectancy, quality of life and diminishment in incidence of blastic crises, which severely endanger life.
DOK1.
2p13.1 Docking protein 1, is a protein which engages in the downstream signalling pathway of tyrosine kinases, being this protein a scaffold protein which assists in the assembly of signalling complexes Table 1 . BCR-ABL1 fusion protein interacts with various other molecules, a selection of them along with a small description of them is shown above, shedding light about the targets this protein possesses, and the possible roles of these proteins in the development of the disease. Fig. 1 . Graph depicting the stochastic matrix of the BCR protein interactions; in the y-axis we may find the initial state protein and the x-axis represents the molecule towards each of the i-th initial molecule/state will move to in the next step. HSPA8  STUB1  RB1  AP2M1  BCR  TP53  ABL1  KIAA1429  HOXA9  IGSF21  CCDC183  FES  MLLT4  MCM4  GRB2  CRKL  HSP90AA1  EZR  CEP128  WDR48  MAOA  SYNC  CSNK2A2  COMMD1  LNX1  TSG101  KIT  PIK3R1  SLA2  GABRR1  PDZK1  CBL  IL3  SCAI  GAB2  WEE1  JPH4  DPF2  SOS1  CRK  VPS28  XPO1  DOK1 BCR-associated interaction probabilities distribution. Fig. 4 . This graph shows the stationary probabilities distribution of ABL1-associated proteins in different moments of time, with the x-axis representing the various molecules with which ABL1 interacts, y-axis the probabilities and the different lines, the moments at which the probabilities were computed. ABI1  ACTA1  AP2B1  ATR  BCR  CASP9  CCND2  CDON  CRKL  DDX5  DVL2  EMD  ERBB2  EWSR1  FUS  GRB10  HIPK2  HSPA8  ILF3  KIAA1429  LRRK1  MDM2  MTOR  NCK1  NEDD9  PAK2  PCNA  PIK3R1  PRKCZ  PSMA4  PTGES3  RAD9A  RB1  RPL37  RTFDC1  SH3KBP1  SHE  SORBS1  SPRR2A  SRPK2  STUB1  TOPBP1  TUB  VAV1  XRCC6  YWHAE  YWHAZ ABL1-associated proteins probabilities distribution. ABL1  EGFR  HSPA8  SHC1  CRK  BRCA1  YWHAQ  CRKL  YAP1  TRIM25  NTRK1  MDM4  SOS1  YWHAE  PTPN6  YWHAG  PLCG1  PCNA  VAV1  CFTR  ATM  YWHAH  CDK1  EPS15  SFN  PRKDC  ERBB4  TSG101  TOPBP1  MCM6  INPP5D  EMD  DDX5  MCM2  AP2B1  TMPO  SORBS2  SOCS3  PXN  GAB2  COMMD1  NCOA3  GRB10  SPTA1  NEDD9  EGLN3  ESR2  FOS  ABI2  EPHB2  STON2  DAPK1  NAGK  SPAG9  CSNK2A2  CDC42 Stationary probabilities of BCR-ABL1 chimeric protein's protein interactions. Subnetwork of proteins. Fig. 7 . Network showing the JAK/STAT signalling pathway (Rawlings, Rosler, & Harrison, 2004) and the potential sites of its inhibition: JAK1 inhibition by filgotinib (depicting one of many drugs which could be potentially used) (PubChem, 2020), gefitinib as an EGFR inhibitor (PubChem, 2020) and IFNG as a promoter of SOCS1 expression.
